Interaction of PPARG Pro12Ala with dietary fat influences plasma lipids in subjects at cardiometabolic risk

Journal of Lipid Research

Volumn 52, Issue 12, 2011, Pages 2298-2303

  AlSaleh, Aseel ^a   O'Dell, Sandra D ^a   Frost, Gary S ^b   Griffin, Bruce A ^c   Lovegrove, Julie A ^d   Jebb, Susan A ^e   Sanders, Thomas A B ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d UNIVERSITY OF READING   (United Kingdom)

^e MRC HUMAN NUTRITION RESEARCH   (United Kingdom)

Author keywords

Gene nutrient interaction; Peroxisome proliferator activated receptor ; Polyunsaturated fatty acid; PPAR ; Saturated fatty acid; Single nucleotide polymorphism

Indexed keywords

ALANINE; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOUNSATURATED FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYUNSATURATED FATTY ACID; PROLINE; SATURATED FATTY ACID; TRIACYLGLYCEROL;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; EATING HABIT; FAT INTAKE; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; LIPID DIET; MALE; METABOLIC SYNDROME X; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CARDIOVASCULAR DISEASES; DIETARY FATS; FATTY ACIDS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HABITS; HUMANS; LIPIDS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA;

EID: 81855173655     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P019281     Document Type: Article

References (23)

1. Desvergne, B., and W. Wahli. 1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20: 649-688. (Pubitemid 30650602)
2. Xu, H. E., M. H. Lambert, V. G. Montana, D. J. Parks, S. G. Blanchard, P. J. Brown, D. D. Sternbach, J. M. Lehmann, G. B. Wisely, T. M. Willson, et al. 1999. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell. 3: 397-403. (Pubitemid 29290680)
3. Semple, R. K., V. K. Chatterjee, and S. O'Rahilly. 2006. PPARγ and human metabolic disease. J. Clin. Invest. 116: 581-589.
4. Vidal-Puig, A., M. Jimenez-Linan, B. B. Lowell, A. Hamann, E. Hu, B. Spiegelman, J. S. Flier, and D. E. Moller. 1996. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J. Clin. Invest. 97: 2553-2561. (Pubitemid 26187343)
5. NCBI dbSNP [database]. Accessed December 15, 2010, at: http://www.ncbi.nlm.nih.gov/snp.
6. Altshuler, D., J. N. Hirschhorn, M. Klannemark, C. M. Lindgren, M. C. Vohl, J. Nemesh, C. R. Lane, S. F. Schaffner, S. Bolk, C. Brewer, et al. 2000. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26: 76-80.
7. Tönjes, A., M. Scholz, M. Loeffler, and M. Stumvoll. 2006. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with prediabetic phenotypes: metaanalysis of 57 studies on nondiabetic individuals. Diabetes Care. 29: 2489-2497. (Pubitemid 44912258)
8. Masud, S., S. Ye, and S. A. S. Group. 2003. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J. Med. Genet. 40: 773-780. (Pubitemid 37311078)
9. Luan, J., P. O. Browne, A. H. Harding, D. J. Halsall, S. O'Rahilly, V. K. Chatterjee, and N. J. Wareham. 2001. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes. 50: 686-689. (Pubitemid 32195237)
10. Memisoglu, A., F. B. Hu, S. E. Hankinson, J. E. Manson, I. De Vivo, W. C. Willett, and D. J. Hunter. 2003. Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum. Mol. Genet. 12: 2923-2929. (Pubitemid 37442020)
11. Deeb, S. S., L. Fajas, M. Nemoto, J. Pihlajamäki, L. Mykkänen, J. Kuusisto, M. Laakso, W. Fujimoto, and J. Auwerx. 1998. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20: 284-287. (Pubitemid 28507675)
12. Masugi, J., Y. Tamori, H. Mori, T. Koike, and M. Kasuga. 2000. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione- induced adipogenesis. Biochem. Biophys. Res. Commun. 268: 178-182. (Pubitemid 30116630)
13. Kast-Woelbern, H. R., S. L. Dana, R. M. Cesario, L. Sun, L. Y. de Grandpre, M. E. Brooks, D. L. Osburn, A. Reifel-Miller, K. Klausing, and M. D. Leibowitz. 2004. Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis. J. Biol. Chem. 279: 23908-23915. (Pubitemid 38725248)
14. Ogata, M., M. Tsujita, M. A. Hossain, N. Akita, F. J. Gonzalez, B. Staels, S. Suzuki, T. Fukutomi, G. Kimura, and S. Yokoyama. 2009. On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis. 205: 413-419.
15. Schoonjans, K., J. Peinado-Onsurbe, A. M. Lefebvre, R. A. Heyman, M. Briggs, S. Deeb, B. Staels, and J. Auwerx. 1996. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15: 5336-5348. (Pubitemid 26336216)
16. Jebb, S. A., J. A. Lovegrove, B. A. Griffin, G. S. Frost, C. S. Moore, M. D. Chatfield, L. J. Bluck, C. M. Williams, and T. A. Sanders. RISCK Study Group. 2010. Effect of changing the amount and type of fat and carbohydrate on insulin sensitivity and cardiovascular risk: the RISCK (Reading, Imperial, Surrey, Cambridge, and Kings) trial. Am. J. Clin. Nutr. 92: 748-758.
17. Bouchard-Mercier, A., G. Godin, B. Lamarche, L. Pérusse, and M. C. Vohl. 2011. Effects of peroxisome proliferator-activated receptors, dietary fat intakes and gene-diet interactions on peak particle diameters of low-density lipoproteins. J. Nutrigenet. Nutrigenomics. 4: 36-48.
18. Moore, C., R. Gitau, L. Goff, F. J. Lewis, M. D. Griffin, M. D. Chatfield, S. A. Jebb, G. S. Frost, T. A. Sanders, B. A. Griffin, et al. RISCK Study Group. 2009. Successful manipulation of the quality and quantity of fat and carbohydrate consumed by free-living individuals using a food exchange model. J. Nutr. 139: 1534-1540.
19. Alberti, K. G., P. Zimmet, and J. Shaw. 2006. Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet. Med. 23: 469-480.
20. Vega, G. L., E. Groszek, R. Wolf, and S. M. Grundy. 1982. Influence of polyunsaturated fats on composition of plasma lipoproteins and apolipoproteins. J. Lipid Res. 23: 811-822. (Pubitemid 13244355)
21. Ovalle, F., and D. S. Bell. 2002. Lipoprotein effects of different thiazolidinediones in clinical practice. Endocr. Pract. 8: 406-410. (Pubitemid 35423126)
22. Harris, W. S., G. Lu, G. S. Rambjor, A. I. Walen, J. A. Ontko, Q. Chang, and S. L. Windsor. 1997. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Am. J. Clin. Nutr. 66: 254-260. (Pubitemid 27360322)
23. Lindi, V., U. Schwab, A. Louheranta, M. Laakso, B. Vessby, K. Hermansen, L. Storlien, G. Riccardi, and A. Rivellese. KANWU Study Group. 2003. Impact of the Pro12Ala polymorphism of the PPAR-gamma2 gene on serum triacylglycerol response to n-3 fatty acid supplementation. Mol. Genet. Metab. 79: 52-60. (Pubitemid 36579441)